Table 2 Immune checkpoint inhibitors approved for clinical use up to 2021, according to www.fda.gov
From: Blockade of novel immune checkpoints and new therapeutic combinations to boost antitumor immunity
Target | Drug name | Indication | Brand name (company) |
|---|---|---|---|
CTLA-4 | Ipilimumab | Melanoma; metastatic melanoma | Yervoy (Bristol-Myers Squibb Co.) |
CTLA-4 + PD-1 | Ipilimumab + nivolumab | HCC; metastatic CRC; metastatic melanoma; metastatic RCC; metastatic NSCLC; malignant pleural mesothelioma | Yervoy + Opdivo (Bristol-Myers Squibb Co.) |
PD-1 | Nivolumab | HCC; Hodgkin lymphoma; metastatic CRC; metastatic melanoma; melanoma; metastatic RCC; metastatic urothelial carcinoma; metastatic HNSCC; metastatic SCLC; metastatic NSCLC; ESCC | Opdivo (Bristol-Myers Squibb Co.) |
PD-1 | Pembrolizumab | HCC; Merkel cell carcinoma; NSCLC; metastatic squamous NSCLC; RCC; melanoma; metastatic gastric cancer; metastatic gastroesophageal junction adenocarcinoma; metastatic urothelial carcinoma; metastatic cervical cancer; Hodgkin lymphoma; metastatic NSCLC; metastatic endometrial cancer; CRC; NMIBC; pancreatic cancer; primary mediastinal B-cell lymphoma; metastatic HNSCC; metastatic tumor mutational burden-high solid tumors; metastatic cSCC, metastatic TNBC | Keytruda (Merck & Co. Inc.) |
PD-1 | Cemiplimab | Metastatic cSCC | Libtayo (Regeneron Pharmaceuticals Inc. / Sanofi-Aventis SA) |
PD-L1 | Atezolizumab | Metastatic TNBC; metastatic NSCLC; SCLC; metastatic urothelial cancer; HCC; metastatic melanoma | Tecentriq (Genentech Inc. / Roche Registration Ltd.) |
PD-L1 | Durvalumab | SCLC; metastatic urothelial cancer; NSCLC | Imfinzi (AstraZeneca Pharmaceuticals LP) |
PD-L1 | Avelumab | Metastatic RCC; metastatic urothelial cancer; Merkel cell carcinoma | Bavencio (Merck KGaA / Pfizer Inc.) |